NCT03443453View on ClinicalTrials.gov

A Bioavailability Study of MIV-711 Oral Formulations in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 19, 2018

Primary Completion Date

February 17, 2018

Study Completion Date

February 17, 2018

Conditions
Healthy
Interventions
DRUG

MIV-711

MIV-711 administered as tablets and capsules at four occasions

Trial Locations (1)

68502

Celerion, Lincoln

Sponsors

Lead Sponsor

Medivir
All Listed Sponsors
lead

Medivir

INDUSTRY

NCT03443453 - A Bioavailability Study of MIV-711 Oral Formulations in Healthy Volunteers | Biotech Hunter | Biotech Hunter